^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Vumon (teniposide)

i
Other names: vm 26, VM-26, VM26
Company:
BMS
Drug class:
Topoisomerase II inhibitor
Related drugs:
1m
Multimodal treatment with thiotepa, bevacizumab, teniposide, and tunlametinib in a patient with neurofibromatosis type 1-associated oligodendroglioma: a rare case report. (PubMed, Anticancer Drugs)
As of June 2025, the patient has achieved a CR with a progression-free survival of 9 months before experiencing disease recurrence. This rare case of NF1-associated oligodendroglioma was managed with thiotepa, bevacizumab, teniposide, and tunlametinib, highlighting the potential of MEK inhibition in NF1-related gliomas.
Journal
|
NF1 (Neurofibromin 1)
|
Avastin (bevacizumab) • Kolupin (tunlametinib) • Vumon (teniposide) • thiotepa
1m
Teniposide combined with bevacizumab for the treatment of recurrent high-grade MGMT promoter unmethylated glioma: A single-center prospective study (ChiCTR2500108634)
P=N/A, N=20, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
New trial
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
Avastin (bevacizumab) • Vumon (teniposide)
2ms
New P2/3 trial
|
Rituxan (rituximab) • Inokai (orelabrutinib) • Vumon (teniposide)
3ms
Triggering mitotic catastrophe by podophyllotoxin induces apoptosis in oral squamous cell carcinoma. (PubMed, Arch Oral Biol)
This study provides compelling evidence supporting the potential therapeutic significance of inducing MC-mediated apoptosis in OSCC. The results underscore the role of PPT and its derivatives, such as etoposide and teniposide, in targeting rapidly dividing cancer cells through interference with mitotic progression, offering insights into novel therapeutic strategies for oral cancer.
Journal
|
CHEK2 (Checkpoint kinase 2) • BAX (BCL2-associated X protein) • ANXA5 (Annexin A5) • CCNB1 (Cyclin B1)
|
etoposide IV • Vumon (teniposide)
4ms
Teniposide Triggers DNA Repair Inhibition by Binding and Ubiquitination of Apurinic/Apyrimidinic Endonuclease 1 to Boost Oxidative DNA Damage for Lung Cancer Destruction. (PubMed, ACS Pharmacol Transl Sci)
In summary, these data make a strong argument for the notion that Ten/VM-26-mediated inhibition of APEX1 contributes to DNA damage and thereby achieves favorable antilung cancer effects, wherein Ten/VM-26 could down-regulate APEX1 by binding and ubiquitination. The current study presents a critical target and mechanism for Ten/VM-26-mediated antilung cancer therapy.
Journal
|
APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1)
|
Vumon (teniposide)
4ms
New P4 trial
|
cisplatin • Vumon (teniposide)
4ms
New trial
|
Vumon (teniposide) • thiotepa • busulfan
5ms
Trial completion
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • cytarabine • carmustine • Vumon (teniposide)
8ms
Differences in transcriptome characteristics and drug repositioning of Alzheimer's disease according to sex. (PubMed, Neurobiol Dis)
The characteristics of the transcriptome in peripheral blood and single-cell transcriptome in the prefrontal cortex exhibit significant differences between male and female patients with AD, which providing a basis for future sex stratified treatment of AD.
Journal
|
BASP1 (Brain Abundant Membrane Attached Signal Protein 1)
|
Vumon (teniposide) • Synribo (omacetaxine mepesuccinate)
8ms
Bioinformatics screened of biomarkers for the prognosis of hepatocellular carcinoma. (PubMed, Cancer Biomark)
Hub genes were enriched in various cell types. Trametinib, selumetinib, RDEA119, and teniposide were identified as potential drugs for LIHC treatment.ConclusionCDC20, TOP2A, CDK1, CAT, TAT, and FTCD may contribute to LIHC development and serve as novel prognostic biomarkers.
Journal
|
TOP2A (DNA topoisomerase 2-alpha) • CDC20 (Cell Division Cycle 20) • CDK1 (Cyclin-dependent kinase 1) • FTCD (Formimidoyltransferase Cyclodeaminase)
|
Mekinist (trametinib) • Koselugo (selumetinib) • refametinib (BAY86-9766) • Vumon (teniposide)
8ms
A prospective, single-center, single-arm clinical study evaluating the efficacy and safety of teniposide combined with RCHOP in newly diagnosed diffuse large B-cell lymphoma patients with high risk of central nervous system relapse (ChiCTR2500099874)
P=N/A, N=47, Not yet recruiting, The first affiliated hospital Zhejiang University school of medicine; The first affiliated hospital Zhejiang University school of medicine
New trial
|
CD5 (CD5 Molecule)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Vumon (teniposide) • vindesine
9ms
AMPK in Chemoradiotherapy-Induced Oral Mucositis. (PubMed, J Oral Pathol Med)
AMPK emerges as a crucial regulator in OM post radiotherapy and chemotherapy, implicating sister chromatid separation, where DCs may play a pivotal role. Aloisine and Teniposide appear promising for OM prevention or treatment associated with these treatments.
Journal
|
AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1) • PRKAA2 (Protein Kinase AMP-Activated Catalytic Subunit Alpha 2)
|
Vumon (teniposide)